



ASX Release

26 July 2007

AVX AUDIO BROADCAST

You are invited to a front row seat at our presentation titled “**AVX-Releases ATC Phase IIb Clinical Trial Update**” by **Dr Jonathan Coates, Chief Scientific Officer** and **Dr Susan Cox, Head of Development**. Conveniently, you don't have to leave your home or office to attend.

To listen, simply click on the link below:

<http://www.brr.com.au/event/AVX/1243/25744/wmp/udoftj5dww>

Receive alerts on future announcements, click below.

[Boardroomradio Alerts](#)

The presentation details are as follows;

- **AVX – Releases ATC Phase IIb Clinical Trial Update**
- **Dr Jonathan Coates and Dr Susan Cox**
- **Thursday 26 July 2007, 3.00PM AEST**

Access archived presentations on demand by visiting www.brr.com.au

Boardroomradio also offers a free Podcast subscription, check the website for details.

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Mr Rod North
Bourse Communications
+ 61 (03) 9510-8309

www.avexa.com.au

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV infections and has an exclusive option to license TargetDrug's lead CCR5 inhibitor, Nifeviroc.